Orexo sees very limited exposure to the UK and the British pound


Uppsala, Sweden – June 21, 2016

In response to recent week´s media attention to companies exposure to brexit and
GBP Orexo AB (publ) today clarifies that its exposure to the UK and thereby
fluctuations in the GBP is very limited. Orexo has no direct income in GBP and
has only limited indirect exposure to GBP through the Abstral® partner, Kyowa
Kirin’s (former Prostrakan), sales of Abstral in the UK. Royalties from sales of
Abstral in the UK amounts to less than 1 percent of Orexo’s annual net revenue
and is invoiced by Orexo in euro.

Earlier Orexo has earned one-off Abstral milestone payments in GBP and hence
Orexo was historically more exposed to GBP.

Contact Information:
Henrik Juuel, EVP and Chief Financial Officer
Tel: +46 (0)18-780 88 00, E-mail: ir@orexo.com

Lena Wange, IR & Communications Manager
Tel: +46 (0)18-780 88 00, E-mail: ir@orexo.com

About Orexo

Orexo is a specialty pharmaceutical company commercializing its proprietary
product Zubsolv® for maintenance treatment of opioid dependence in the US.
Zubsolv is an advanced formulation of buprenorphine and naloxone using Orexo’s
unique knowledge and expertise in sublingual drug delivery. R&D is focusing on
reformulation of known substances to new improved products that meet great unmet
medical needs by using its patented proprietary technologies. Orexo’s share is
listed on Nasdaq Stockholm Exchange Mid Cap (STO:ORX) and is available as ADRs
on OTCQX (ORXOY) in the US. Orexo’s global headquarters and R&D are based in
Uppsala, Sweden.

For information about Orexo, please visit www.orexo.com. To read more about
Zubsolv and opioid dependence, please visit www.zubsolv.com and
www.outthemonster.com.

Orexo AB (publ) discloses the information provided herein pursuant to the
Financial Instruments Trading Act. The information was submitted for publication
at 6:30 a.m. CET on June 21, 2016.

Attachments

06214210.pdf